Orion Corporation will publish its Financial Statement Release 2024 on Tuesday, 25 February 2025.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2025 are as follows:
| Interim Report January-March 2025 | Wednesday 23 April 2025 |
| Half-Year Financial Report January-June 2025 | Friday 18 July 2025 |
| Interim Report January-September 2025 | Tuesday 28 October 2025 |
The Financial Statements and the Report of the Board of Directors for 2024 will be published on the Company's website at the latest in week 11/2025.
The Annual General Meeting is planned to be held on Thursday, 3 April 2025.
Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.
Orion Corporation
| Liisa Hurme President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
